EyePoint, Inc. Common Stock (EYPT) Stock Price

EYPTStock

$5.00−58.83%52W

Market Cap$419.63M

P/E—

PEG Ratio—

Div yield—

Beta1.60

EYPT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-77.33%

Price vs S&P 500 (4W)-62.33%

VGM Score12.60

Book Value / Share (Quarterly)$1.96

P/TBV (Annual)1.24x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.83%

Cash Flow / Share (Quarterly)$-3.19

Price vs S&P 500 (YTD)-85.30%

Gross Margin (TTM)41.77%

Net Profit Margin (TTM)-10994.73%

EPS (TTM)$-3.74

10-Day Avg Trading Volume10.51M

EPS Excl Extra (TTM)$-3.74

Revenue Growth (5Y)-1.85%

EPS (Annual)$-3.17

ROI (Annual)-75.78%

Gross Margin (Annual)93.41%

Net Profit Margin (5Y Avg)-320.16%

Cash / Share (Quarterly)$2.12

Revenue Growth QoQ (YoY)-90.49%

ROA (Last FY)-63.73%

Revenue Growth TTM (YoY)-94.63%

EBITD / Share (TTM)$-3.86

ROE (5Y Avg)-55.80%

Operating Margin (TTM)-11365.22%

Cash Flow / Share (Annual)$-2.94

P/B Ratio6.92x

P/B Ratio (Quarterly)7.20x

Net Income / Employee (Annual)$-1,083,900

EV / Revenue (TTM)373.37x

Net Interest Coverage (TTM)-95.46x

ROA (TTM)-108.34%

EV / EBITDA (TTM)159.47x

EPS Incl Extra (Annual)$-3.17

Current Ratio (Annual)8.88x

Quick Ratio (Quarterly)4.33x

3-Month Avg Trading Volume2.31M

52-Week Price Return-58.83%

Revenue / Employee (TTM)$13,000

Tangible BV / Share (Quarterly)$2.83

P/S Ratio (Annual)36.72x

Asset Turnover (Annual)0.09x

52-Week High$19.11

Operating Margin (5Y Avg)-333.51%

EPS Excl Extra (Annual)$-3.17

CapEx CAGR (5Y)55.57%

Tangible BV CAGR (5Y)35.00%

26-Week Price Return-66.09%

Quick Ratio (Annual)8.28x

13-Week Price Return-61.89%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.50x

Enterprise Value$1.04B

Revenue / Share Growth (5Y)-30.71%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)29.31%

Revenue / Employee (Annual)$146,600

Inventory Turnover (Annual)1.00x

Pretax Margin (Annual)-738.53%

Cash / Share (Annual)$3.70

3-Month Return Std Dev154.71%

Gross Margin (5Y Avg)86.50%

Net Income / Employee (TTM)$-1,432,900

ROE (Last FY)-75.78%

Net Interest Coverage (Annual)-27.76x

EPS Basic Excl Extra (Annual)$-3.17

P/FCF (TTM)20.34x

Receivables Turnover (TTM)7.85x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.74

Receivables Turnover (Annual)49.87x

ROI (TTM)-135.81%

P/S Ratio (TTM)412.98x

Pretax Margin (5Y Avg)-319.91%

Revenue / Share (Annual)$0.43

Tangible BV / Share (Annual)$2.83

Price vs S&P 500 (52W)-77.14%

Year-to-Date Return-73.34%

5-Day Price Return-10.97%

EPS Normalized (Annual)$-3.17

ROA (5Y Avg)-38.76%

Net Profit Margin (Annual)-739.42%

Month-to-Date Return-60.24%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-3.29

Operating Margin (Annual)-775.98%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-48.55%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.74

P/TBV (Quarterly)1.24x

P/B Ratio (Annual)4.94x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)-10989.85%

Book Value / Share (Annual)$3.70

Price vs S&P 500 (13W)-64.69%

Beta1.60x

P/FCF (Annual)113.59x

Revenue / Share (TTM)$0.03

ROE (TTM)-135.81%

52-Week Low$3.95

vGradeD

gGradeF

mGradeF

vgmGradeF

EYPT Earnings Surprise History

Q2 25-0.85est. -0.80

Q3 25-0.85est. -0.77

Q4 25-0.81est. -0.75

Q1 26-0.99est. -0.81

Q2 26-1.09est. -0.96

EYPT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.28

4.30

Industry Peers — Lab Analytical Instruments(26)

Symbol	Value Score	Growth Score	Momentum Score	Price
EYPTEyePoint, Inc. Common Stock	D	F	F	$5.00
AAgilent Technologies Inc.	D	C	B	$154.77
WATWaters Corp	D	C	B	$414.44
ILMNIllumina Inc	D	D	A	$224.99
MTDMettler-Toledo International	D	C	B	$1402.25
RVTYRevvity, Inc.	C	D	B	$124.84
BIOBio-Rad Laboratories, Inc.Class A	C	D	B	$390.34
BIO.BBio-Rad Laboratories, Inc. Class B	C	D	B	$365.08
AVTRAvantor, Inc.	B	F	A	$14.42
BRKRBruker Corporation	D	D	B	$56.85
TXG10x Genomics, Inc. Class A Common Stock	F	D	A	$64.72
ALMRAlamar Biosciences, Inc. Common Stock	—	—	A	$33.02
CTKBCytek Biosciences, Inc. Common Stock	C	C	C	$4.58
PACBPacific Biosciences of California, Inc.	D	C	C	$1.52
MASS908 Devices Inc. Common Stock	C	C	A	$11.00
PREPrenetics Global Limited Class A Ordinary Share	C	D	A	$23.25
LABStandard BioTools Inc. Common Stock	A	F	D	$0.65
QTRXQuanterix Corporation Common Stock	A	C	C	$2.79
SEERSeer, Inc. Class A Common Stock	C	D	C	$2.04
NAUTNautilus Biotechnolgy, Inc. Common Stock	—	—	C	$0.88
RPIDRapid Micro Biosystems, Inc. Class A Common Stock	C	B	D	$1.66
PRPOPrecipio, Inc. Common Stock	C	A	A	$30.85
HBIOHarvard Bioscience Inc	B	F	A	$7.58
ASTCAstrotech Corporation (DE) Common Stock	C	C	A	$7.10
BNGOBionano Genomics, Inc. Common Stock	A	C	C	$1.25
HLTHTema Healthcare AI ETF	—	F	D	$29.92
PRENWPrenetics Global Limited Warrant	—	—	D	$0.01

About EyePoint, Inc. Common Stock

EyePoint Inc is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases, with the goal of improving patient outcomes while reducing treatment burden and follow-up care frequency. Its pipeline includes DURAVYU, a sustained-release product candidate for retinal diseases, and EYP-2301, an early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting vascular stability in conditions like wet age-related macular degeneration.